Hormone replacement therapy in women with systemic lupus erythematosus and risk of cardiovascular disease

Lupus

Volumn 18, Issue 4, 2009, Pages 313-317

  Hochman, J ^a   Urowitz, M B ^a   Ibanz D ^a   Gladman, Dafina D ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Cardiovascular disease; Hormone replacement therapy; Systemic lupus erythematosus

Indexed keywords

ANTIMALARIAL AGENT; HORMONE DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; STEROID;

ADULT; ARTICLE; CANADA; CARDIOVASCULAR RISK; CIGARETTE SMOKING; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE ACTIVITY; DISEASE PREDISPOSITION; DRUG SAFETY; FEMALE; HORMONE SUBSTITUTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; ANTIBODIES, ANTIPHOSPHOLIPID; CANADA; COHORT STUDIES; CORONARY ARTERY DISEASE; DATABASES, FACTUAL; ESTROGEN REPLACEMENT THERAPY; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; KAPLAN-MEIERS ESTIMATE; LUPUS COAGULATION INHIBITOR; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; MULTIVARIATE ANALYSIS; POSTMENOPAUSE; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; TIME FACTORS;

EID: 62749186067     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203308097475     Document Type: Article

References (21)

1. Julkunen H. Hormone replacement therapy in women with rheumatic diseases. Scand J Rheumatol 2000; 29: 146-153.
2. Mok CC, Lau CS, Ho CTK, Lee KW, Mok MY, Wong RW. Safety of hormonal replacement therapy in postmenopausal patients with systemic lupus erythematosus. Scand J Rheumatol 1998; 27: 342-346.
3. Kreidstein S, Urowitz MB, Gladman DD, Gough J. Hormone replacement therapy in systemic lupus erythematosus. J Rheumatol 1997; 24: 2149-2152.
4. Buyon JP, Petri M, Kim M, et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: A randomized trial. Ann Intern Med 2005; 142: 953-962.
5. Nikpour M, Urowitz MB, Gladman DD. Premature atherosclerosis in systemic lupus erythematosus. Rheum Dis Clin North Am 2005; 31: 329-354.
6. Almehed K, Forsblad DH, Kvist G, Ohlsson C, Carlsten H. Prevalence and risk factors of osteoporosis in female SLE patientsextended report. Rheumatology (Oxford) 2007; 46: 1185-1190.
7. Hulley S, Grady D, Bush T, et al.; for theHeart and Estrogen/progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280: 605-613.
8. Writing Group for The Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's health initiative randomized controlled trial. JAMA 2002; 288: 321-333.
9. Naftolin F, Schneider HPG, Sturdee DW, et al. Guidelines for hormone treatment of women in the menopausal transition and beyond. Position statement by the Executive of the International Menopause Society. Climacteric 2004; 7: 333-337.
10. Manzi S, Meilahn EN, Rairie JE, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: Comparison with the Framingham Study. Am J Epidemiol 1997; 145: 408-415.
11. Ward MM. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum 1999; 42: 338-346.
12. Wajed J, Ahmad Y, Durrington PN, Bruce IN. Prevention of cardiovascular disease in systemic lupus erythematosus - proposed guidelines for risk factor management. Rheumatology 2004; 43: 7-12.
13. Gladman DD, Ibañez D, Urowitz MB. SLE disease activity index 2000. J Rheumatol 2002; 29: 288-291.
14. Urowitz MB, Ibañez D, Gladman DD. Atherosclerotic vascular events (AVE) in a single large lupus cohort: Prevalence and risk factors. J Rheumatol 2007; 34: 70-75.
15. Bruce IN, Gladman DD, Urowitz MB. Premature atherosclerosis in systemic lupus erythematosus. Rheum Dis Clin North Am 2000; 26: 257-277.
16. Esdaile JM, Abrahamowicz M, Grodzicky T, et al. Traditional framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001; 44: 2331-2337.
17. Fernandez M, Calvo-Alen J, Bertoli AM, et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA L II): Relationship between vascular events and the use of hormone replacement therapy in postmenopausal women. J Clin Rheumatol 2007; 13: 261-265.
18. Bruce IN, Urowitz MB, Gladman DD, Ibañez D, Steiner G. Risk factors for coronary heart disease in women with systemic lupus erythematosus: The Toronto Risk Factor Study. Arthritis Rheum 2003; 48: 3159-3167.
19. Doria A, Iaccarino L, Sarzi-Puttini P, Atzeni F, Turriel M, Petri M. Cardiac involvement in systemic lupus erythematosus. Lupus 2005; 14: 683-686.
20. Hahn BH. Systemic lupus erythematosus and accelerated atherosclerosis. N Engl J Med 2003; 349: 2379-2380.
21. Wathen CN, Feig DS, Feightner JW, Abramson BL, Cheung AC. Hormone replacement therapy for the primary prevention of chronic diseases: recommendation statement from the Canadian Task Force on Preventive HealthCare. CMAJ (Canadian Medical Association Journal) 2004; 170: 1535-1539.